nodes	percent_of_prediction	percent_of_DWPC	metapath
Formoterol—CYP2A6—Methoxsalen—hematologic cancer	0.065	0.104	CbGbCtD
Formoterol—CYP2A6—Ifosfamide—hematologic cancer	0.0474	0.0756	CbGbCtD
Formoterol—CYP2C9—Bexarotene—hematologic cancer	0.0347	0.0553	CbGbCtD
Formoterol—CYP2A6—Prednisolone—hematologic cancer	0.0316	0.0504	CbGbCtD
Formoterol—CYP2D6—Lomustine—hematologic cancer	0.0295	0.047	CbGbCtD
Formoterol—CYP2C9—Idarubicin—hematologic cancer	0.0288	0.0458	CbGbCtD
Formoterol—CYP2D6—Idarubicin—hematologic cancer	0.0263	0.0419	CbGbCtD
Formoterol—CYP2C19—Bortezomib—hematologic cancer	0.0256	0.0408	CbGbCtD
Formoterol—CYP2D6—Hydroxyurea—hematologic cancer	0.0224	0.0356	CbGbCtD
Formoterol—CYP2C19—Thalidomide—hematologic cancer	0.0223	0.0355	CbGbCtD
Formoterol—CYP2C9—Bortezomib—hematologic cancer	0.0213	0.0339	CbGbCtD
Formoterol—CYP2C19—Teniposide—hematologic cancer	0.0213	0.0339	CbGbCtD
Formoterol—CYP2C19—Ifosfamide—hematologic cancer	0.0196	0.0313	CbGbCtD
Formoterol—CYP2D6—Bortezomib—hematologic cancer	0.0194	0.031	CbGbCtD
Formoterol—CYP2C19—Imatinib—hematologic cancer	0.0187	0.0299	CbGbCtD
Formoterol—CYP2A6—Dexamethasone—hematologic cancer	0.0186	0.0297	CbGbCtD
Formoterol—CYP2C9—Thalidomide—hematologic cancer	0.0185	0.0295	CbGbCtD
Formoterol—CYP2C9—Teniposide—hematologic cancer	0.0177	0.0282	CbGbCtD
Formoterol—CYP2C9—Ifosfamide—hematologic cancer	0.0163	0.026	CbGbCtD
Formoterol—CYP2C9—Imatinib—hematologic cancer	0.0156	0.0248	CbGbCtD
Formoterol—CYP2D6—Imatinib—hematologic cancer	0.0142	0.0227	CbGbCtD
Formoterol—CYP2C9—Nilotinib—hematologic cancer	0.0142	0.0226	CbGbCtD
Formoterol—CYP2D6—Nilotinib—hematologic cancer	0.0129	0.0206	CbGbCtD
Formoterol—CYP2D6—Vinorelbine—hematologic cancer	0.0128	0.0205	CbGbCtD
Formoterol—CYP2C19—Prednisone—hematologic cancer	0.0123	0.0197	CbGbCtD
Formoterol—CYP2C9—Cisplatin—hematologic cancer	0.00793	0.0126	CbGbCtD
Formoterol—CYP2D6—Vinblastine—hematologic cancer	0.00791	0.0126	CbGbCtD
Formoterol—CYP2C19—Dexamethasone—hematologic cancer	0.00771	0.0123	CbGbCtD
Formoterol—CYP2C9—Dexamethasone—hematologic cancer	0.00641	0.0102	CbGbCtD
Formoterol—CYP2D6—Dexamethasone—hematologic cancer	0.00586	0.00934	CbGbCtD
Formoterol—CYP2D6—Doxorubicin—hematologic cancer	0.00486	0.00775	CbGbCtD
Formoterol—Isoprenaline—PIK3R1—hematologic cancer	0.00238	1	CrCbGaD
Formoterol—Cardiac disorder—Epirubicin—hematologic cancer	3.59e-05	0.00011	CcSEcCtD
Formoterol—Rhinitis—Doxorubicin—hematologic cancer	3.59e-05	0.000109	CcSEcCtD
Formoterol—Hypersensitivity—Prednisolone—hematologic cancer	3.56e-05	0.000109	CcSEcCtD
Formoterol—Pharyngitis—Doxorubicin—hematologic cancer	3.55e-05	0.000108	CcSEcCtD
Formoterol—Dyspepsia—Dexamethasone—hematologic cancer	3.55e-05	0.000108	CcSEcCtD
Formoterol—Dyspepsia—Betamethasone—hematologic cancer	3.55e-05	0.000108	CcSEcCtD
Formoterol—Urinary tract disorder—Doxorubicin—hematologic cancer	3.53e-05	0.000108	CcSEcCtD
Formoterol—Urticaria—Triamcinolone—hematologic cancer	3.53e-05	0.000108	CcSEcCtD
Formoterol—Oedema peripheral—Doxorubicin—hematologic cancer	3.53e-05	0.000108	CcSEcCtD
Formoterol—Dysgeusia—Methotrexate—hematologic cancer	3.52e-05	0.000108	CcSEcCtD
Formoterol—Asthenia—Etoposide—hematologic cancer	3.52e-05	0.000107	CcSEcCtD
Formoterol—Connective tissue disorder—Doxorubicin—hematologic cancer	3.52e-05	0.000107	CcSEcCtD
Formoterol—Body temperature increased—Triamcinolone—hematologic cancer	3.52e-05	0.000107	CcSEcCtD
Formoterol—Anaphylactic shock—Prednisone—hematologic cancer	3.51e-05	0.000107	CcSEcCtD
Formoterol—Oedema—Prednisone—hematologic cancer	3.51e-05	0.000107	CcSEcCtD
Formoterol—Urethral disorder—Doxorubicin—hematologic cancer	3.51e-05	0.000107	CcSEcCtD
Formoterol—Nausea—Irinotecan—hematologic cancer	3.5e-05	0.000107	CcSEcCtD
Formoterol—Nausea—Mitoxantrone—hematologic cancer	3.5e-05	0.000107	CcSEcCtD
Formoterol—Immune system disorder—Epirubicin—hematologic cancer	3.49e-05	0.000107	CcSEcCtD
Formoterol—Infection—Prednisone—hematologic cancer	3.49e-05	0.000107	CcSEcCtD
Formoterol—Mediastinal disorder—Epirubicin—hematologic cancer	3.49e-05	0.000106	CcSEcCtD
Formoterol—Gastrointestinal disorder—Dexamethasone—hematologic cancer	3.48e-05	0.000106	CcSEcCtD
Formoterol—Gastrointestinal disorder—Betamethasone—hematologic cancer	3.48e-05	0.000106	CcSEcCtD
Formoterol—Back pain—Methotrexate—hematologic cancer	3.48e-05	0.000106	CcSEcCtD
Formoterol—Fatigue—Dexamethasone—hematologic cancer	3.48e-05	0.000106	CcSEcCtD
Formoterol—Fatigue—Betamethasone—hematologic cancer	3.48e-05	0.000106	CcSEcCtD
Formoterol—Pruritus—Etoposide—hematologic cancer	3.47e-05	0.000106	CcSEcCtD
Formoterol—Arrhythmia—Epirubicin—hematologic cancer	3.46e-05	0.000105	CcSEcCtD
Formoterol—Pain—Dexamethasone—hematologic cancer	3.45e-05	0.000105	CcSEcCtD
Formoterol—Pain—Betamethasone—hematologic cancer	3.45e-05	0.000105	CcSEcCtD
Formoterol—Visual impairment—Doxorubicin—hematologic cancer	3.45e-05	0.000105	CcSEcCtD
Formoterol—Nervous system disorder—Prednisone—hematologic cancer	3.45e-05	0.000105	CcSEcCtD
Formoterol—Tachycardia—Prednisone—hematologic cancer	3.43e-05	0.000105	CcSEcCtD
Formoterol—Skin disorder—Prednisone—hematologic cancer	3.41e-05	0.000104	CcSEcCtD
Formoterol—Nausea—Gemcitabine—hematologic cancer	3.41e-05	0.000104	CcSEcCtD
Formoterol—Vomiting—Cisplatin—hematologic cancer	3.4e-05	0.000104	CcSEcCtD
Formoterol—Mental disorder—Epirubicin—hematologic cancer	3.39e-05	0.000103	CcSEcCtD
Formoterol—Rash—Cisplatin—hematologic cancer	3.37e-05	0.000103	CcSEcCtD
Formoterol—Dermatitis—Cisplatin—hematologic cancer	3.37e-05	0.000103	CcSEcCtD
Formoterol—Malnutrition—Epirubicin—hematologic cancer	3.37e-05	0.000103	CcSEcCtD
Formoterol—Diarrhoea—Etoposide—hematologic cancer	3.35e-05	0.000102	CcSEcCtD
Formoterol—Ill-defined disorder—Methotrexate—hematologic cancer	3.34e-05	0.000102	CcSEcCtD
Formoterol—Feeling abnormal—Betamethasone—hematologic cancer	3.32e-05	0.000101	CcSEcCtD
Formoterol—Feeling abnormal—Dexamethasone—hematologic cancer	3.32e-05	0.000101	CcSEcCtD
Formoterol—Cardiac disorder—Doxorubicin—hematologic cancer	3.32e-05	0.000101	CcSEcCtD
Formoterol—Tension—Epirubicin—hematologic cancer	3.3e-05	0.000101	CcSEcCtD
Formoterol—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.3e-05	0.000101	CcSEcCtD
Formoterol—Gastrointestinal pain—Betamethasone—hematologic cancer	3.3e-05	0.000101	CcSEcCtD
Formoterol—Dysgeusia—Epirubicin—hematologic cancer	3.3e-05	0.000101	CcSEcCtD
Formoterol—Hypersensitivity—Triamcinolone—hematologic cancer	3.28e-05	0.0001	CcSEcCtD
Formoterol—Nervousness—Epirubicin—hematologic cancer	3.27e-05	9.98e-05	CcSEcCtD
Formoterol—Back pain—Epirubicin—hematologic cancer	3.26e-05	9.94e-05	CcSEcCtD
Formoterol—Malaise—Methotrexate—hematologic cancer	3.24e-05	9.9e-05	CcSEcCtD
Formoterol—Dizziness—Etoposide—hematologic cancer	3.24e-05	9.89e-05	CcSEcCtD
Formoterol—Muscle spasms—Epirubicin—hematologic cancer	3.24e-05	9.88e-05	CcSEcCtD
Formoterol—Immune system disorder—Doxorubicin—hematologic cancer	3.23e-05	9.86e-05	CcSEcCtD
Formoterol—Mediastinal disorder—Doxorubicin—hematologic cancer	3.23e-05	9.84e-05	CcSEcCtD
Formoterol—Urticaria—Betamethasone—hematologic cancer	3.21e-05	9.78e-05	CcSEcCtD
Formoterol—Urticaria—Dexamethasone—hematologic cancer	3.21e-05	9.78e-05	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.2e-05	9.77e-05	CcSEcCtD
Formoterol—Dizziness—Prednisolone—hematologic cancer	3.2e-05	9.76e-05	CcSEcCtD
Formoterol—Arrhythmia—Doxorubicin—hematologic cancer	3.2e-05	9.76e-05	CcSEcCtD
Formoterol—Asthenia—Triamcinolone—hematologic cancer	3.19e-05	9.73e-05	CcSEcCtD
Formoterol—Body temperature increased—Betamethasone—hematologic cancer	3.19e-05	9.73e-05	CcSEcCtD
Formoterol—Body temperature increased—Dexamethasone—hematologic cancer	3.19e-05	9.73e-05	CcSEcCtD
Formoterol—Abdominal pain—Dexamethasone—hematologic cancer	3.19e-05	9.73e-05	CcSEcCtD
Formoterol—Abdominal pain—Betamethasone—hematologic cancer	3.19e-05	9.73e-05	CcSEcCtD
Formoterol—Nausea—Cisplatin—hematologic cancer	3.18e-05	9.7e-05	CcSEcCtD
Formoterol—Insomnia—Prednisone—hematologic cancer	3.18e-05	9.7e-05	CcSEcCtD
Formoterol—Pruritus—Triamcinolone—hematologic cancer	3.15e-05	9.6e-05	CcSEcCtD
Formoterol—Cough—Methotrexate—hematologic cancer	3.14e-05	9.58e-05	CcSEcCtD
Formoterol—Mental disorder—Doxorubicin—hematologic cancer	3.14e-05	9.57e-05	CcSEcCtD
Formoterol—Ill-defined disorder—Epirubicin—hematologic cancer	3.12e-05	9.53e-05	CcSEcCtD
Formoterol—Vomiting—Etoposide—hematologic cancer	3.12e-05	9.51e-05	CcSEcCtD
Formoterol—Malnutrition—Doxorubicin—hematologic cancer	3.12e-05	9.51e-05	CcSEcCtD
Formoterol—Agitation—Epirubicin—hematologic cancer	3.09e-05	9.44e-05	CcSEcCtD
Formoterol—Dyspepsia—Prednisone—hematologic cancer	3.09e-05	9.44e-05	CcSEcCtD
Formoterol—Rash—Etoposide—hematologic cancer	3.09e-05	9.43e-05	CcSEcCtD
Formoterol—Dermatitis—Etoposide—hematologic cancer	3.09e-05	9.42e-05	CcSEcCtD
Formoterol—Headache—Etoposide—hematologic cancer	3.07e-05	9.37e-05	CcSEcCtD
Formoterol—Arthralgia—Methotrexate—hematologic cancer	3.06e-05	9.35e-05	CcSEcCtD
Formoterol—Myalgia—Methotrexate—hematologic cancer	3.06e-05	9.35e-05	CcSEcCtD
Formoterol—Chest pain—Methotrexate—hematologic cancer	3.06e-05	9.35e-05	CcSEcCtD
Formoterol—Tension—Doxorubicin—hematologic cancer	3.06e-05	9.33e-05	CcSEcCtD
Formoterol—Dysgeusia—Doxorubicin—hematologic cancer	3.05e-05	9.31e-05	CcSEcCtD
Formoterol—Rash—Prednisolone—hematologic cancer	3.05e-05	9.3e-05	CcSEcCtD
Formoterol—Dermatitis—Prednisolone—hematologic cancer	3.05e-05	9.29e-05	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.04e-05	9.28e-05	CcSEcCtD
Formoterol—Malaise—Epirubicin—hematologic cancer	3.04e-05	9.27e-05	CcSEcCtD
Formoterol—Fatigue—Prednisone—hematologic cancer	3.03e-05	9.24e-05	CcSEcCtD
Formoterol—Headache—Prednisolone—hematologic cancer	3.03e-05	9.24e-05	CcSEcCtD
Formoterol—Discomfort—Methotrexate—hematologic cancer	3.03e-05	9.23e-05	CcSEcCtD
Formoterol—Nervousness—Doxorubicin—hematologic cancer	3.03e-05	9.23e-05	CcSEcCtD
Formoterol—Back pain—Doxorubicin—hematologic cancer	3.01e-05	9.2e-05	CcSEcCtD
Formoterol—Constipation—Prednisone—hematologic cancer	3e-05	9.17e-05	CcSEcCtD
Formoterol—Muscle spasms—Doxorubicin—hematologic cancer	3e-05	9.14e-05	CcSEcCtD
Formoterol—Palpitations—Epirubicin—hematologic cancer	2.98e-05	9.08e-05	CcSEcCtD
Formoterol—Dizziness—Triamcinolone—hematologic cancer	2.94e-05	8.97e-05	CcSEcCtD
Formoterol—Cough—Epirubicin—hematologic cancer	2.94e-05	8.97e-05	CcSEcCtD
Formoterol—Anaphylactic shock—Methotrexate—hematologic cancer	2.94e-05	8.96e-05	CcSEcCtD
Formoterol—Infection—Methotrexate—hematologic cancer	2.92e-05	8.9e-05	CcSEcCtD
Formoterol—Nausea—Etoposide—hematologic cancer	2.91e-05	8.89e-05	CcSEcCtD
Formoterol—Hypertension—Epirubicin—hematologic cancer	2.91e-05	8.87e-05	CcSEcCtD
Formoterol—Feeling abnormal—Prednisone—hematologic cancer	2.9e-05	8.83e-05	CcSEcCtD
Formoterol—Asthenia—Dexamethasone—hematologic cancer	2.89e-05	8.83e-05	CcSEcCtD
Formoterol—Asthenia—Betamethasone—hematologic cancer	2.89e-05	8.83e-05	CcSEcCtD
Formoterol—Ill-defined disorder—Doxorubicin—hematologic cancer	2.89e-05	8.82e-05	CcSEcCtD
Formoterol—Nervous system disorder—Methotrexate—hematologic cancer	2.88e-05	8.79e-05	CcSEcCtD
Formoterol—Gastrointestinal pain—Prednisone—hematologic cancer	2.87e-05	8.77e-05	CcSEcCtD
Formoterol—Nausea—Prednisolone—hematologic cancer	2.87e-05	8.76e-05	CcSEcCtD
Formoterol—Arthralgia—Epirubicin—hematologic cancer	2.87e-05	8.75e-05	CcSEcCtD
Formoterol—Myalgia—Epirubicin—hematologic cancer	2.87e-05	8.75e-05	CcSEcCtD
Formoterol—Chest pain—Epirubicin—hematologic cancer	2.87e-05	8.75e-05	CcSEcCtD
Formoterol—Agitation—Doxorubicin—hematologic cancer	2.86e-05	8.74e-05	CcSEcCtD
Formoterol—Anxiety—Epirubicin—hematologic cancer	2.86e-05	8.72e-05	CcSEcCtD
Formoterol—Pruritus—Betamethasone—hematologic cancer	2.85e-05	8.71e-05	CcSEcCtD
Formoterol—Pruritus—Dexamethasone—hematologic cancer	2.85e-05	8.71e-05	CcSEcCtD
Formoterol—Skin disorder—Methotrexate—hematologic cancer	2.85e-05	8.7e-05	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	2.85e-05	8.69e-05	CcSEcCtD
Formoterol—Discomfort—Epirubicin—hematologic cancer	2.83e-05	8.64e-05	CcSEcCtD
Formoterol—Vomiting—Triamcinolone—hematologic cancer	2.83e-05	8.63e-05	CcSEcCtD
Formoterol—Malaise—Doxorubicin—hematologic cancer	2.81e-05	8.57e-05	CcSEcCtD
Formoterol—Rash—Triamcinolone—hematologic cancer	2.8e-05	8.55e-05	CcSEcCtD
Formoterol—Dry mouth—Epirubicin—hematologic cancer	2.8e-05	8.55e-05	CcSEcCtD
Formoterol—Dermatitis—Triamcinolone—hematologic cancer	2.8e-05	8.55e-05	CcSEcCtD
Formoterol—Urticaria—Prednisone—hematologic cancer	2.79e-05	8.52e-05	CcSEcCtD
Formoterol—Headache—Triamcinolone—hematologic cancer	2.79e-05	8.5e-05	CcSEcCtD
Formoterol—Abdominal pain—Prednisone—hematologic cancer	2.78e-05	8.48e-05	CcSEcCtD
Formoterol—Body temperature increased—Prednisone—hematologic cancer	2.78e-05	8.48e-05	CcSEcCtD
Formoterol—Diarrhoea—Dexamethasone—hematologic cancer	2.76e-05	8.42e-05	CcSEcCtD
Formoterol—Diarrhoea—Betamethasone—hematologic cancer	2.76e-05	8.42e-05	CcSEcCtD
Formoterol—Palpitations—Doxorubicin—hematologic cancer	2.75e-05	8.4e-05	CcSEcCtD
Formoterol—Anaphylactic shock—Epirubicin—hematologic cancer	2.75e-05	8.39e-05	CcSEcCtD
Formoterol—Oedema—Epirubicin—hematologic cancer	2.75e-05	8.39e-05	CcSEcCtD
Formoterol—Hypotension—Methotrexate—hematologic cancer	2.74e-05	8.37e-05	CcSEcCtD
Formoterol—Infection—Epirubicin—hematologic cancer	2.73e-05	8.33e-05	CcSEcCtD
Formoterol—Cough—Doxorubicin—hematologic cancer	2.72e-05	8.3e-05	CcSEcCtD
Formoterol—Nervous system disorder—Epirubicin—hematologic cancer	2.69e-05	8.22e-05	CcSEcCtD
Formoterol—Hypertension—Doxorubicin—hematologic cancer	2.69e-05	8.21e-05	CcSEcCtD
Formoterol—Tachycardia—Epirubicin—hematologic cancer	2.68e-05	8.18e-05	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.68e-05	8.16e-05	CcSEcCtD
Formoterol—Skin disorder—Epirubicin—hematologic cancer	2.67e-05	8.14e-05	CcSEcCtD
Formoterol—Dizziness—Dexamethasone—hematologic cancer	2.67e-05	8.14e-05	CcSEcCtD
Formoterol—Dizziness—Betamethasone—hematologic cancer	2.67e-05	8.14e-05	CcSEcCtD
Formoterol—Insomnia—Methotrexate—hematologic cancer	2.66e-05	8.1e-05	CcSEcCtD
Formoterol—Arthralgia—Doxorubicin—hematologic cancer	2.65e-05	8.09e-05	CcSEcCtD
Formoterol—Chest pain—Doxorubicin—hematologic cancer	2.65e-05	8.09e-05	CcSEcCtD
Formoterol—Myalgia—Doxorubicin—hematologic cancer	2.65e-05	8.09e-05	CcSEcCtD
Formoterol—Anxiety—Doxorubicin—hematologic cancer	2.64e-05	8.07e-05	CcSEcCtD
Formoterol—Nausea—Triamcinolone—hematologic cancer	2.64e-05	8.06e-05	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.63e-05	8.04e-05	CcSEcCtD
Formoterol—Discomfort—Doxorubicin—hematologic cancer	2.62e-05	8e-05	CcSEcCtD
Formoterol—Dyspnoea—Methotrexate—hematologic cancer	2.62e-05	7.99e-05	CcSEcCtD
Formoterol—Somnolence—Methotrexate—hematologic cancer	2.61e-05	7.97e-05	CcSEcCtD
Formoterol—Dry mouth—Doxorubicin—hematologic cancer	2.59e-05	7.92e-05	CcSEcCtD
Formoterol—Hypersensitivity—Prednisone—hematologic cancer	2.59e-05	7.9e-05	CcSEcCtD
Formoterol—Dyspepsia—Methotrexate—hematologic cancer	2.58e-05	7.89e-05	CcSEcCtD
Formoterol—Hypotension—Epirubicin—hematologic cancer	2.57e-05	7.84e-05	CcSEcCtD
Formoterol—Vomiting—Betamethasone—hematologic cancer	2.57e-05	7.83e-05	CcSEcCtD
Formoterol—Vomiting—Dexamethasone—hematologic cancer	2.57e-05	7.83e-05	CcSEcCtD
Formoterol—Rash—Dexamethasone—hematologic cancer	2.54e-05	7.76e-05	CcSEcCtD
Formoterol—Rash—Betamethasone—hematologic cancer	2.54e-05	7.76e-05	CcSEcCtD
Formoterol—Anaphylactic shock—Doxorubicin—hematologic cancer	2.54e-05	7.76e-05	CcSEcCtD
Formoterol—Oedema—Doxorubicin—hematologic cancer	2.54e-05	7.76e-05	CcSEcCtD
Formoterol—Dermatitis—Dexamethasone—hematologic cancer	2.54e-05	7.76e-05	CcSEcCtD
Formoterol—Dermatitis—Betamethasone—hematologic cancer	2.54e-05	7.76e-05	CcSEcCtD
Formoterol—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.54e-05	7.74e-05	CcSEcCtD
Formoterol—Fatigue—Methotrexate—hematologic cancer	2.53e-05	7.72e-05	CcSEcCtD
Formoterol—Headache—Dexamethasone—hematologic cancer	2.53e-05	7.71e-05	CcSEcCtD
Formoterol—Headache—Betamethasone—hematologic cancer	2.53e-05	7.71e-05	CcSEcCtD
Formoterol—Infection—Doxorubicin—hematologic cancer	2.53e-05	7.71e-05	CcSEcCtD
Formoterol—Asthenia—Prednisone—hematologic cancer	2.52e-05	7.69e-05	CcSEcCtD
Formoterol—Pain—Methotrexate—hematologic cancer	2.51e-05	7.66e-05	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.5e-05	7.64e-05	CcSEcCtD
Formoterol—Nervous system disorder—Doxorubicin—hematologic cancer	2.49e-05	7.61e-05	CcSEcCtD
Formoterol—Pruritus—Prednisone—hematologic cancer	2.49e-05	7.59e-05	CcSEcCtD
Formoterol—Insomnia—Epirubicin—hematologic cancer	2.49e-05	7.58e-05	CcSEcCtD
Formoterol—Tachycardia—Doxorubicin—hematologic cancer	2.48e-05	7.57e-05	CcSEcCtD
Formoterol—Skin disorder—Doxorubicin—hematologic cancer	2.47e-05	7.54e-05	CcSEcCtD
Formoterol—Dyspnoea—Epirubicin—hematologic cancer	2.45e-05	7.48e-05	CcSEcCtD
Formoterol—Somnolence—Epirubicin—hematologic cancer	2.44e-05	7.45e-05	CcSEcCtD
Formoterol—Feeling abnormal—Methotrexate—hematologic cancer	2.42e-05	7.38e-05	CcSEcCtD
Formoterol—Dyspepsia—Epirubicin—hematologic cancer	2.42e-05	7.38e-05	CcSEcCtD
Formoterol—Diarrhoea—Prednisone—hematologic cancer	2.4e-05	7.34e-05	CcSEcCtD
Formoterol—Gastrointestinal pain—Methotrexate—hematologic cancer	2.4e-05	7.33e-05	CcSEcCtD
Formoterol—Nausea—Dexamethasone—hematologic cancer	2.4e-05	7.31e-05	CcSEcCtD
Formoterol—Nausea—Betamethasone—hematologic cancer	2.4e-05	7.31e-05	CcSEcCtD
Formoterol—Hypotension—Doxorubicin—hematologic cancer	2.38e-05	7.25e-05	CcSEcCtD
Formoterol—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.37e-05	7.24e-05	CcSEcCtD
Formoterol—Fatigue—Epirubicin—hematologic cancer	2.37e-05	7.23e-05	CcSEcCtD
Formoterol—Pain—Epirubicin—hematologic cancer	2.35e-05	7.17e-05	CcSEcCtD
Formoterol—Constipation—Epirubicin—hematologic cancer	2.35e-05	7.17e-05	CcSEcCtD
Formoterol—Urticaria—Methotrexate—hematologic cancer	2.33e-05	7.12e-05	CcSEcCtD
Formoterol—Dizziness—Prednisone—hematologic cancer	2.32e-05	7.09e-05	CcSEcCtD
Formoterol—Abdominal pain—Methotrexate—hematologic cancer	2.32e-05	7.08e-05	CcSEcCtD
Formoterol—Body temperature increased—Methotrexate—hematologic cancer	2.32e-05	7.08e-05	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.32e-05	7.07e-05	CcSEcCtD
Formoterol—Insomnia—Doxorubicin—hematologic cancer	2.3e-05	7.02e-05	CcSEcCtD
Formoterol—Dyspnoea—Doxorubicin—hematologic cancer	2.27e-05	6.92e-05	CcSEcCtD
Formoterol—Feeling abnormal—Epirubicin—hematologic cancer	2.26e-05	6.91e-05	CcSEcCtD
Formoterol—Somnolence—Doxorubicin—hematologic cancer	2.26e-05	6.9e-05	CcSEcCtD
Formoterol—Gastrointestinal pain—Epirubicin—hematologic cancer	2.25e-05	6.86e-05	CcSEcCtD
Formoterol—Dyspepsia—Doxorubicin—hematologic cancer	2.24e-05	6.83e-05	CcSEcCtD
Formoterol—Vomiting—Prednisone—hematologic cancer	2.23e-05	6.82e-05	CcSEcCtD
Formoterol—Rash—Prednisone—hematologic cancer	2.22e-05	6.76e-05	CcSEcCtD
Formoterol—Dermatitis—Prednisone—hematologic cancer	2.21e-05	6.75e-05	CcSEcCtD
Formoterol—Headache—Prednisone—hematologic cancer	2.2e-05	6.72e-05	CcSEcCtD
Formoterol—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.2e-05	6.7e-05	CcSEcCtD
Formoterol—Fatigue—Doxorubicin—hematologic cancer	2.19e-05	6.69e-05	CcSEcCtD
Formoterol—Urticaria—Epirubicin—hematologic cancer	2.18e-05	6.66e-05	CcSEcCtD
Formoterol—Constipation—Doxorubicin—hematologic cancer	2.17e-05	6.63e-05	CcSEcCtD
Formoterol—Pain—Doxorubicin—hematologic cancer	2.17e-05	6.63e-05	CcSEcCtD
Formoterol—Body temperature increased—Epirubicin—hematologic cancer	2.17e-05	6.63e-05	CcSEcCtD
Formoterol—Abdominal pain—Epirubicin—hematologic cancer	2.17e-05	6.63e-05	CcSEcCtD
Formoterol—Hypersensitivity—Methotrexate—hematologic cancer	2.16e-05	6.6e-05	CcSEcCtD
Formoterol—Asthenia—Methotrexate—hematologic cancer	2.11e-05	6.43e-05	CcSEcCtD
Formoterol—Feeling abnormal—Doxorubicin—hematologic cancer	2.1e-05	6.39e-05	CcSEcCtD
Formoterol—Nausea—Prednisone—hematologic cancer	2.09e-05	6.37e-05	CcSEcCtD
Formoterol—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.08e-05	6.34e-05	CcSEcCtD
Formoterol—Pruritus—Methotrexate—hematologic cancer	2.08e-05	6.34e-05	CcSEcCtD
Formoterol—Hypersensitivity—Epirubicin—hematologic cancer	2.02e-05	6.18e-05	CcSEcCtD
Formoterol—Urticaria—Doxorubicin—hematologic cancer	2.02e-05	6.16e-05	CcSEcCtD
Formoterol—Abdominal pain—Doxorubicin—hematologic cancer	2.01e-05	6.13e-05	CcSEcCtD
Formoterol—Body temperature increased—Doxorubicin—hematologic cancer	2.01e-05	6.13e-05	CcSEcCtD
Formoterol—Diarrhoea—Methotrexate—hematologic cancer	2.01e-05	6.13e-05	CcSEcCtD
Formoterol—Asthenia—Epirubicin—hematologic cancer	1.97e-05	6.02e-05	CcSEcCtD
Formoterol—Pruritus—Epirubicin—hematologic cancer	1.94e-05	5.93e-05	CcSEcCtD
Formoterol—Dizziness—Methotrexate—hematologic cancer	1.94e-05	5.93e-05	CcSEcCtD
Formoterol—Diarrhoea—Epirubicin—hematologic cancer	1.88e-05	5.74e-05	CcSEcCtD
Formoterol—Hypersensitivity—Doxorubicin—hematologic cancer	1.87e-05	5.72e-05	CcSEcCtD
Formoterol—Vomiting—Methotrexate—hematologic cancer	1.87e-05	5.7e-05	CcSEcCtD
Formoterol—Rash—Methotrexate—hematologic cancer	1.85e-05	5.65e-05	CcSEcCtD
Formoterol—Dermatitis—Methotrexate—hematologic cancer	1.85e-05	5.64e-05	CcSEcCtD
Formoterol—Headache—Methotrexate—hematologic cancer	1.84e-05	5.61e-05	CcSEcCtD
Formoterol—Asthenia—Doxorubicin—hematologic cancer	1.82e-05	5.57e-05	CcSEcCtD
Formoterol—Dizziness—Epirubicin—hematologic cancer	1.82e-05	5.54e-05	CcSEcCtD
Formoterol—Pruritus—Doxorubicin—hematologic cancer	1.8e-05	5.49e-05	CcSEcCtD
Formoterol—Vomiting—Epirubicin—hematologic cancer	1.75e-05	5.33e-05	CcSEcCtD
Formoterol—Nausea—Methotrexate—hematologic cancer	1.74e-05	5.32e-05	CcSEcCtD
Formoterol—Diarrhoea—Doxorubicin—hematologic cancer	1.74e-05	5.31e-05	CcSEcCtD
Formoterol—Rash—Epirubicin—hematologic cancer	1.73e-05	5.29e-05	CcSEcCtD
Formoterol—Dermatitis—Epirubicin—hematologic cancer	1.73e-05	5.28e-05	CcSEcCtD
Formoterol—Headache—Epirubicin—hematologic cancer	1.72e-05	5.25e-05	CcSEcCtD
Formoterol—Dizziness—Doxorubicin—hematologic cancer	1.68e-05	5.13e-05	CcSEcCtD
Formoterol—Nausea—Epirubicin—hematologic cancer	1.63e-05	4.98e-05	CcSEcCtD
Formoterol—Vomiting—Doxorubicin—hematologic cancer	1.62e-05	4.93e-05	CcSEcCtD
Formoterol—Rash—Doxorubicin—hematologic cancer	1.6e-05	4.89e-05	CcSEcCtD
Formoterol—Dermatitis—Doxorubicin—hematologic cancer	1.6e-05	4.89e-05	CcSEcCtD
Formoterol—Headache—Doxorubicin—hematologic cancer	1.59e-05	4.86e-05	CcSEcCtD
Formoterol—Nausea—Doxorubicin—hematologic cancer	1.51e-05	4.61e-05	CcSEcCtD
Formoterol—ADRB1—Signaling Pathways—CD86—hematologic cancer	7.9e-06	0.000187	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—NUP98—hematologic cancer	7.87e-06	0.000186	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—JAK2—hematologic cancer	7.86e-06	0.000186	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—HES1—hematologic cancer	7.79e-06	0.000184	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GSTT1—hematologic cancer	7.75e-06	0.000183	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—NCOR1—hematologic cancer	7.75e-06	0.000183	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CD86—hematologic cancer	7.73e-06	0.000183	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ADCY7—hematologic cancer	7.7e-06	0.000182	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—NCOA3—hematologic cancer	7.7e-06	0.000182	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—JAK2—hematologic cancer	7.69e-06	0.000182	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CSF2—hematologic cancer	7.66e-06	0.000181	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—FGF1—hematologic cancer	7.66e-06	0.000181	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—NUP214—hematologic cancer	7.65e-06	0.000181	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ADCY7—hematologic cancer	7.64e-06	0.000181	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—NCOA3—hematologic cancer	7.64e-06	0.000181	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	7.63e-06	0.00018	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—HES1—hematologic cancer	7.62e-06	0.00018	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—NUP214—hematologic cancer	7.58e-06	0.000179	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—NCOR1—hematologic cancer	7.58e-06	0.000179	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—SDC1—hematologic cancer	7.57e-06	0.000179	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—FOXO1—hematologic cancer	7.55e-06	0.000179	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—IL2—hematologic cancer	7.55e-06	0.000178	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PDGFRB—hematologic cancer	7.54e-06	0.000178	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	7.5e-06	0.000177	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—FGF1—hematologic cancer	7.5e-06	0.000177	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CSF2—hematologic cancer	7.5e-06	0.000177	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ABCG2—hematologic cancer	7.49e-06	0.000177	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—MTR—hematologic cancer	7.49e-06	0.000177	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—PIK3CB—hematologic cancer	7.46e-06	0.000176	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—MTR—hematologic cancer	7.43e-06	0.000176	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ABCG2—hematologic cancer	7.43e-06	0.000176	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PDGFRA—hematologic cancer	7.42e-06	0.000175	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—JAK1—hematologic cancer	7.4e-06	0.000175	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PRKCG—hematologic cancer	7.4e-06	0.000175	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—FOXO1—hematologic cancer	7.39e-06	0.000175	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—IL2—hematologic cancer	7.38e-06	0.000175	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PDGFRB—hematologic cancer	7.37e-06	0.000174	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ENO2—hematologic cancer	7.35e-06	0.000174	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—PIK3CB—hematologic cancer	7.3e-06	0.000173	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ENO2—hematologic cancer	7.29e-06	0.000172	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PDGFRA—hematologic cancer	7.26e-06	0.000172	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	7.24e-06	0.000171	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—JAK1—hematologic cancer	7.24e-06	0.000171	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PRKCG—hematologic cancer	7.24e-06	0.000171	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—MTHFR—hematologic cancer	7.16e-06	0.000169	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	7.14e-06	0.000169	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GSTT1—hematologic cancer	7.13e-06	0.000169	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GSTT1—hematologic cancer	7.07e-06	0.000167	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—SDC1—hematologic cancer	6.97e-06	0.000165	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	6.96e-06	0.000164	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IL2RA—hematologic cancer	6.91e-06	0.000163	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—SDC1—hematologic cancer	6.91e-06	0.000163	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—IL2—hematologic cancer	6.86e-06	0.000162	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	6.83e-06	0.000162	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TERT—hematologic cancer	6.83e-06	0.000161	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IL2RA—hematologic cancer	6.76e-06	0.00016	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—IL2—hematologic cancer	6.71e-06	0.000159	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TERT—hematologic cancer	6.68e-06	0.000158	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PDGFB—hematologic cancer	6.67e-06	0.000158	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	6.6e-06	0.000156	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PDGFB—hematologic cancer	6.52e-06	0.000154	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TSC2—hematologic cancer	6.52e-06	0.000154	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	6.51e-06	0.000154	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CD44—hematologic cancer	6.44e-06	0.000152	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—NQO1—hematologic cancer	6.44e-06	0.000152	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TSC2—hematologic cancer	6.37e-06	0.000151	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	6.31e-06	0.000149	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—FGFR3—hematologic cancer	6.27e-06	0.000148	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	6.23e-06	0.000147	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MAPK14—hematologic cancer	6.21e-06	0.000147	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—FGFR3—hematologic cancer	6.13e-06	0.000145	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYCS—hematologic cancer	6.09e-06	0.000144	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ESR1—hematologic cancer	6.09e-06	0.000144	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MAPK14—hematologic cancer	6.07e-06	0.000144	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	6.06e-06	0.000143	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—FN1—hematologic cancer	6.01e-06	0.000142	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PIK3CG—hematologic cancer	6.01e-06	0.000142	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ESR1—hematologic cancer	5.95e-06	0.000141	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—BAD—hematologic cancer	5.94e-06	0.00014	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—NFKBIA—hematologic cancer	5.94e-06	0.00014	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—NQO1—hematologic cancer	5.92e-06	0.00014	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CD44—hematologic cancer	5.92e-06	0.00014	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—NOTCH1—hematologic cancer	5.88e-06	0.000139	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—FN1—hematologic cancer	5.88e-06	0.000139	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CD44—hematologic cancer	5.87e-06	0.000139	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—NQO1—hematologic cancer	5.87e-06	0.000139	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—BAD—hematologic cancer	5.81e-06	0.000137	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—NFKBIA—hematologic cancer	5.81e-06	0.000137	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CD80—hematologic cancer	5.76e-06	0.000136	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—NOTCH1—hematologic cancer	5.76e-06	0.000136	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—KIT—hematologic cancer	5.75e-06	0.000136	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PIK3CG—hematologic cancer	5.75e-06	0.000136	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—NRAS—hematologic cancer	5.75e-06	0.000136	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	5.75e-06	0.000136	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PTPN11—hematologic cancer	5.65e-06	0.000134	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CD80—hematologic cancer	5.64e-06	0.000133	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—KIT—hematologic cancer	5.63e-06	0.000133	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PIK3CG—hematologic cancer	5.63e-06	0.000133	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—NRAS—hematologic cancer	5.63e-06	0.000133	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYCS—hematologic cancer	5.61e-06	0.000133	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CREBBP—hematologic cancer	5.57e-06	0.000132	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	5.57e-06	0.000132	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYCS—hematologic cancer	5.56e-06	0.000131	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PTPN11—hematologic cancer	5.53e-06	0.000131	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	5.52e-06	0.000131	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—MAPK3—hematologic cancer	5.51e-06	0.00013	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CREB1—hematologic cancer	5.48e-06	0.000129	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	5.45e-06	0.000129	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—BRAF—hematologic cancer	5.41e-06	0.000128	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—MAPK3—hematologic cancer	5.39e-06	0.000127	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GSTP1—hematologic cancer	5.37e-06	0.000127	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CCL2—hematologic cancer	5.36e-06	0.000127	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CREB1—hematologic cancer	5.36e-06	0.000127	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IL6R—hematologic cancer	5.34e-06	0.000126	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CREBBP—hematologic cancer	5.34e-06	0.000126	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—BRAF—hematologic cancer	5.29e-06	0.000125	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PIK3CD—hematologic cancer	5.29e-06	0.000125	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CCL2—hematologic cancer	5.24e-06	0.000124	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IL6R—hematologic cancer	5.23e-06	0.000124	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CREBBP—hematologic cancer	5.22e-06	0.000123	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—ALB—hematologic cancer	5.22e-06	0.000123	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	5.2e-06	0.000123	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MAP2K1—hematologic cancer	5.09e-06	0.00012	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ABCB1—hematologic cancer	5.08e-06	0.00012	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PIK3CD—hematologic cancer	5.06e-06	0.00012	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—PIK3CA—hematologic cancer	5.01e-06	0.000118	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PIK3R1—hematologic cancer	4.99e-06	0.000118	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MAP2K1—hematologic cancer	4.98e-06	0.000118	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	4.97e-06	0.000117	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—KRAS—hematologic cancer	4.95e-06	0.000117	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PIK3CD—hematologic cancer	4.95e-06	0.000117	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GSTP1—hematologic cancer	4.94e-06	0.000117	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GSTM1—hematologic cancer	4.94e-06	0.000117	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—NCOR1—hematologic cancer	4.94e-06	0.000117	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—PIK3CA—hematologic cancer	4.9e-06	0.000116	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GSTP1—hematologic cancer	4.9e-06	0.000116	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—KRAS—hematologic cancer	4.84e-06	0.000115	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—FGF2—hematologic cancer	4.84e-06	0.000115	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PIK3R1—hematologic cancer	4.78e-06	0.000113	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	4.74e-06	0.000112	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—FGF2—hematologic cancer	4.74e-06	0.000112	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ABCB1—hematologic cancer	4.68e-06	0.000111	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PIK3R1—hematologic cancer	4.67e-06	0.00011	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—JAK2—hematologic cancer	4.64e-06	0.00011	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ABCB1—hematologic cancer	4.64e-06	0.00011	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PIK3CB—hematologic cancer	4.61e-06	0.000109	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—PIK3CA—hematologic cancer	4.55e-06	0.000108	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—JAK2—hematologic cancer	4.54e-06	0.000107	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—NCOR1—hematologic cancer	4.54e-06	0.000107	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GSTM1—hematologic cancer	4.54e-06	0.000107	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MDM2—hematologic cancer	4.53e-06	0.000107	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GSTM1—hematologic cancer	4.5e-06	0.000106	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—NCOR1—hematologic cancer	4.5e-06	0.000106	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—PIK3CA—hematologic cancer	4.45e-06	0.000105	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MDM2—hematologic cancer	4.43e-06	0.000105	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MTOR—hematologic cancer	4.41e-06	0.000104	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PIK3CB—hematologic cancer	4.41e-06	0.000104	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—MTHFR—hematologic cancer	4.36e-06	0.000103	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MTOR—hematologic cancer	4.31e-06	0.000102	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PIK3CB—hematologic cancer	4.31e-06	0.000102	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—HRAS—hematologic cancer	4.21e-06	9.95e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CDKN1B—hematologic cancer	4.14e-06	9.78e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—HRAS—hematologic cancer	4.12e-06	9.74e-05	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—AKT1—hematologic cancer	4.09e-06	9.68e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CASP3—hematologic cancer	4.06e-06	9.59e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IL2—hematologic cancer	4.05e-06	9.57e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CDKN1B—hematologic cancer	4.05e-06	9.57e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—IL6—hematologic cancer	4.03e-06	9.53e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—MTHFR—hematologic cancer	4.01e-06	9.49e-05	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—AKT1—hematologic cancer	4e-06	9.47e-05	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PTEN—hematologic cancer	3.98e-06	9.41e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—MTHFR—hematologic cancer	3.98e-06	9.4e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CASP3—hematologic cancer	3.97e-06	9.38e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IL2—hematologic cancer	3.96e-06	9.37e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CCND1—hematologic cancer	3.95e-06	9.33e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—IL6—hematologic cancer	3.94e-06	9.32e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—JUN—hematologic cancer	3.94e-06	9.31e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CCND1—hematologic cancer	3.86e-06	9.13e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—JUN—hematologic cancer	3.85e-06	9.11e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.84e-06	9.09e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CDKN1A—hematologic cancer	3.82e-06	9.03e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PTEN—hematologic cancer	3.81e-06	9.01e-05	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—EP300—hematologic cancer	3.8e-06	8.97e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CDKN1A—hematologic cancer	3.74e-06	8.83e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MAPK8—hematologic cancer	3.73e-06	8.81e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PTEN—hematologic cancer	3.73e-06	8.81e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—AKT1—hematologic cancer	3.72e-06	8.79e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PIK3CG—hematologic cancer	3.67e-06	8.67e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MAPK8—hematologic cancer	3.65e-06	8.62e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—AKT1—hematologic cancer	3.64e-06	8.6e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—EP300—hematologic cancer	3.63e-06	8.59e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—EP300—hematologic cancer	3.55e-06	8.4e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—SRC—hematologic cancer	3.53e-06	8.35e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.51e-06	8.29e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—SRC—hematologic cancer	3.46e-06	8.17e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—VEGFA—hematologic cancer	3.44e-06	8.14e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—STAT3—hematologic cancer	3.41e-06	8.06e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—NRAS—hematologic cancer	3.4e-06	8.04e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CREBBP—hematologic cancer	3.4e-06	8.03e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PIK3CG—hematologic cancer	3.37e-06	7.97e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—VEGFA—hematologic cancer	3.37e-06	7.96e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PIK3CG—hematologic cancer	3.34e-06	7.9e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—STAT3—hematologic cancer	3.33e-06	7.88e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—NRAS—hematologic cancer	3.33e-06	7.86e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MAPK3—hematologic cancer	3.26e-06	7.7e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PIK3CD—hematologic cancer	3.22e-06	7.62e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MAPK3—hematologic cancer	3.18e-06	7.53e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ALB—hematologic cancer	3.18e-06	7.52e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MYC—hematologic cancer	3.17e-06	7.49e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TGFB1—hematologic cancer	3.16e-06	7.47e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CREBBP—hematologic cancer	3.13e-06	7.39e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CREBBP—hematologic cancer	3.1e-06	7.33e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MYC—hematologic cancer	3.1e-06	7.32e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TGFB1—hematologic cancer	3.09e-06	7.31e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PIK3R1—hematologic cancer	3.04e-06	7.19e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PIK3CD—hematologic cancer	2.96e-06	7.01e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PIK3CD—hematologic cancer	2.94e-06	6.95e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—KRAS—hematologic cancer	2.93e-06	6.92e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ALB—hematologic cancer	2.93e-06	6.92e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ALB—hematologic cancer	2.9e-06	6.86e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—KRAS—hematologic cancer	2.86e-06	6.77e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PIK3CB—hematologic cancer	2.81e-06	6.64e-05	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PIK3CA—hematologic cancer	2.81e-06	6.64e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PIK3R1—hematologic cancer	2.8e-06	6.62e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PIK3R1—hematologic cancer	2.77e-06	6.56e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PIK3CA—hematologic cancer	2.69e-06	6.35e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PIK3CA—hematologic cancer	2.63e-06	6.22e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TP53—hematologic cancer	2.6e-06	6.15e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PIK3CB—hematologic cancer	2.58e-06	6.11e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PIK3CB—hematologic cancer	2.56e-06	6.05e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TP53—hematologic cancer	2.54e-06	6.01e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—HRAS—hematologic cancer	2.49e-06	5.88e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—HRAS—hematologic cancer	2.43e-06	5.75e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PTEN—hematologic cancer	2.43e-06	5.74e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IL6—hematologic cancer	2.38e-06	5.63e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IL6—hematologic cancer	2.33e-06	5.5e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—EP300—hematologic cancer	2.31e-06	5.47e-05	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—AKT1—hematologic cancer	2.29e-06	5.42e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PTEN—hematologic cancer	2.23e-06	5.28e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PTEN—hematologic cancer	2.21e-06	5.23e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—AKT1—hematologic cancer	2.2e-06	5.19e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—AKT1—hematologic cancer	2.15e-06	5.08e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—EP300—hematologic cancer	2.13e-06	5.03e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—EP300—hematologic cancer	2.11e-06	4.99e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PIK3CA—hematologic cancer	1.71e-06	4.05e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.57e-06	3.72e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PIK3CA—hematologic cancer	1.56e-06	3.69e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—AKT1—hematologic cancer	1.4e-06	3.31e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—AKT1—hematologic cancer	1.29e-06	3.04e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—AKT1—hematologic cancer	1.28e-06	3.02e-05	CbGpPWpGaD
